Turning the Tide on an Epidemic: A Native Kentuckian Changes the Deadly Trajectory of HIV Infection by Cook, Dannette Smith
Tell us a little bit about the work you did that earned Science jour-
nal’s Breakthrough of the Year Award in 2011.
I initially went to Lilongwe, Malawi to start the HPTN 052 study 
that led to the “breakthrough” of the year.   The breakthrough 
demonstrated that early antiretroviral therapy can reduce HIV 
transmission to a negative partner by 96%.  My work on the re-
search protocol largely included developing the research proto-
col with our chair (Myron S. Cohen) and then building the local 
team, training, recruiting discordant couples, and supervising 
the implementation of the study.  Much of the recruitment in-
cluded building partnerships with local organizations that per-
form lots of HIV testing, as well as establishing our own testing 
activities.  Our site was the leading enrolling site, and we put 251 
couples on the study.
How has that seminal paper affected the direction of research in 
HIV/AIDS since its publication two years ago?
On an international scale, the WHO has issued a guideline for 
the management of discordant couples largely stating that with-
in all such couples, the HIV infected member should be offered 
treatment.  More broadly, the HPTN 052 study supported ear-
lier initiation of ART for the general population and the latest 
(2013) WHO guidelines support initiation of ART at CD4 of 
500 cells (rather than 350).  Research now focuses on how ear-
lier treatment (or universal treatment of HIV infected patients) 
will reduce HIV transmission on a population level.  Countries, 
like Malawi, have used the “treatment is prevention” message as 
a strong rationale to expand ART treatment to all HIV positive 
pregnant women as this provides a maternal health benefit to 
the mother, as well as a prevention benefit for the infant and any 
HIV negative partner they might have.  
Is treatment of infected partners at higher CD4 counts to prevent 
transmission to non-infected partners now considered standard 
of care?
It is now the WHO recommendation (as well as IAS, DHHS, 
etc) but some countries have not yet moved to 500 cells, due to 
cost considerations and whether or not the health care infra-
structure can accommodate the increased number of patients 
that would need care.   [WHO- World Health Organization, 
IAS- International AIDS Society, DHHS- Department of Health 
and Human Services]
Infection rates in Malawi according to UNAIDS stands at 10%. 
Remarkably, they describe a 55% drop in the 10 years between 
2001 and 2011.  How often do you estimate infection rates?  Do 
you attribute the marked drop in infection rates to more wide-
spread availability of ART?  
The Malawi Ministry of Health conducts HIV prevalence esti-
mates alongside UNAIDS annually.  This is largely based on a 
epidemiology program called “SPECTRUM” that uses inputs 
from regularly collected data to estimate the prevalence.  In ru-
ral South Africa, there was a study that clearly demonstrated 
that HIV incidence decreased according to population coverage 
of ART (Tanser, et al.).  Malawi has even higher coverage than 
seen in this article, so I suspect that many of the reductions are 
due in part to increased ART coverage.  There may be increased 
condom use among known positives that could also contribute 
to the reduction (among other factors). 
In what amount of time would you expect to see a drop in infec-
tion rates with new guidelines?
I suspect the trajectory of reduction in new infections will be 
somewhat slower than with the initial roll out, as the change is 
modest to go from 350 to 500 [CD4 Cell Counts], as compared 
to the initial situation where no one was on therapy to the cur-
rent rates of  approximately 60% coverage of those in need at the 
350 threshold.
You also co-authored another study showing decrease in vertical 
transmission rates in infants whose HIV infected mothers were 
given anti-retroviral treatment for at least 12 weeks prior to de-
livery.  Do pregnant women in Malawi frequently make it to de-
livery without pre-natal care?  How can you target (especially HIV 
infected) pregnant women for pre-natal care prior to 28 weeks of 
pregnancy?  Were the CD4 counts in the study participants also 
liberalized up to a CD4 count of 500? [PMTCT-Prevention of 
Mother to Child Transmission of HIV]
Ninety percent of Malawian women attend at least one antenatal 
visit, although most do not present until the mid-to-late second 
trimester or even in the third trimester (average 26 weeks).  So 
for PMTCT, it is important to start early in pregnancy to opti-
mally reduce transmission to the infant.  Malawi pioneered an 
approach of treating all HIV positive pregnant women regard-
less of CD4 cell count at the initial visit in which they were iden-
tified as positive. (Option B+)  This has resulted in over a 700% 
         r. Mina Hosseinipour did not know her 
research would positively change the trajec-
tory of the worldwide HIV epidemic when 
she graduated with a bachelor’s degree from 
the University of Kentucky in the early 1990’s. 
In fact, it wasn’t until she was a resident in 
internal medicine at Baylor College of Med-
icine that she decided to pursue a career in 
infectious diseases.  
This led her to The University of North Car-
olina (UNC), a world leader in the field of 
infectious diseases, where she completed 
her fellowship and a concomitant Master’s 
of Public Health.  During her third and final 
year of fellowship, she headed to Africa to 
work with the UNC Malawi Project:  a co-
operative between the Lilongwe Ministry of 
Health and UNC to initiate the HIV Preven-
tion Trials Network (HPTN) Study 052.
This landmark study showed that in cou-
ples in which one partner is HIV positive 
and the other is HIV negative (so-called 
“discordant couples”), early anti-retroviral 
treatment (ART) in the affected partner caus-
es a marked drop in infection rates of the 
non-infected partner.   This study was truly a 
game-changer, recognized by the prestigious 
scientific journal Science as their “Break-
through of the Year” in 2011.  The study was 
originally designed to enroll thousands of 
discordant couples to treat and track over a 
period of 5 years.  However, after periodically 
reviewing preliminary data, the NIH stopped 
the study early.  It appeared that the results 
were so profound that it was imperative to 
offer treatment to all patients meeting the en-
rollment criteria.  These results changed the 
trajectory of HIV therapy through the addi-
tion of new treatment guidelines to “scale-up 
ART.”  In fact, the results were so impressive 
that they prompted Dr. Hosseinipour’s boss 
and the lead author on the study, Dr. Myron 
Cohen, to conclude in an interview that “it 
makes you actually believe that you can actu-
ally see the beginning of an epidemic, and the 
end of an epidemic, in one lifetime.”
In addition to this prestigious research, Dr. 
Hosseinipour has also co-authored a study 
showing reduction in transmission of HIV 
from infected mothers to their offspring 
when treated with ART while pregnant.
So here we are, with a new paradigm of 
“treatment as prevention” and celebrating 
one million babies born HIV negative to an 
HIV positive mother through the initiatives 
of PEPFAR.  It is truly a new era for preven-
tion and treatment of HIV around the globe. 
Dare we say, “The Downfall of an Epidemic?”
Dr. Hosseinipour and your correspondent 
were medicine residents together at Baylor 
College of Medicine in Houston.  Your cor-
respondent is pleased and proud to share an 
interview with Hosseinipour regarding both 
her remarkable career and her role in chang-
ing the face of the HIV/AIDS epidemic.
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Dr. Mina Hosseinipour (left) at one of the UNC-Malawi Project sites in Lilongwe, Ma-
lawi.  Pictured with her are two of her Clinical Study Coordinators, Cecelia Kanyama 
(center) and Nasinuku Saukila (right). | Photo provided by Dannette Smith Cook
Tell us a little bit about the work you did that 
earned Science journal’s Breakthrough of the 
Year Award in 2011.
I initially went to Lilongwe, Malawi to start the 
HPTN 052 study that led to the “breakthrough” 
of the year. The breakthrough demonstrated 
that early antiretroviral therapy can reduce HIV 
transmission to a negative partner by 96%.  My 
work on the research protocol largely includ-
ed developing the research protocol with our 
chair (Myron S. Cohen) and then building the 
local team, training, recruiting discordant cou-
ples, and supervising the implementation of the 
study.  Much of the recruitment included build-
ing partnerships with local organizations that 
perform lots of HIV testing, as well as establish-
ing our own testing activities.  Our site was the 
leading enrolling site, and we put 251 couples 
on the study.
How has that seminal paper affected the direction 
of research in HIV/AIDS since its publication two 
years ago?
On an international scale, the WHO has issued 
a guideline for the management of discordant 
couples largely stating that within all such cou-
ples, the HIV infected member should be of-
fered treatment.  More broadly, the HPTN 052 
study supported earlier initiation of ART for the 
general population and the latest (2013) WHO 
guidelines support initiation of ART at CD4 of 
500 cells (rather than 350).  Research now fo-
cuses on how earlier treatment (or universal 
treatment of HIV infected patients) will reduce 
HIV transmission on a population level.  Coun-
tries, like Malawi, have used the “treatment is 
prevention” message as a strong rationale to 
expand ART treatment to all HIV positive preg-
nant women as this provides a maternal health 
benefit to the mother, as well as a prevention 
benefit for the infant and any HIV negative 
partner they might have.  
Is treatment of infected partners at higher CD4 
counts to prevent transmission to non-infected 
partners now considered standard of care?
It is now the WHO recommendation (as well as 
IAS, DHHS, etc) but some countries have not yet 
moved to 500 cells, due to cost considerations 
and whether or not the health care infrastruc-
ture can accommodate the increased number of 
patients that would need care.   [WHO- World 
Health Organization, IAS- International AIDS 
Society, DHHS- Department of Health and Hu-
man Services]
Infection rates in Malawi according to UNAIDS 
stands at 10%.  Remarkably, they describe a 55% 
drop in the 10 years between 2001 and 2011.  How 
often do you estimate infection rates?  Do you 
attribute the marked drop in infection rates to 
more widespread availability of ART?  
The Malawi Ministry of Health conducts HIV 
prevalence estimates alongside UNAIDS an-
nually.  This is largely based on a epidemiology 
program called “SPECTRUM” that uses inputs 
from regularly collected data to estimate the 
prevalence.  In rural South Africa, there was a 
study that clearly demonstrated that HIV inci-
dence decreased according to population cov-
erage of ART (Tanser, et al.).  Malawi has even 
higher coverage than seen in this article, so I 
suspect that many of the reductions are due in 
part to increased ART coverage.  There may 
be increased condom use among known posi-
tives that could also contribute to the reduction 
(among other factors). 
In what amount of time would you expect to see a 
drop in infection rates with new guidelines?
I suspect the trajectory of reduction in new 
infections will be somewhat slower than with 
the initial roll out, as the change is modest to 
go from 350 to 500 [CD4 Cell Counts], as com-
pared to the initial situation where no one was 
on therapy to the current rates of  approximately 
60% coverage of those in need at the 350 thresh-
old.
You also co-authored another study showing de-
crease in vertical transmission rates in infants 
whose HIV infected mothers were given anti-ret-
roviral treatment for at least 12 weeks prior to de-
livery.  Do pregnant women in Malawi frequently 
make it to delivery without pre-natal care?  How 
can you target (especially HIV infected) preg-
nant women for pre-natal care prior to 28 weeks 
of pregnancy?  Were the CD4 counts in the study 
participants also liberalized up to a CD4 count 
of 500? [PMTCT-Prevention of Mother to Child 
Transmission of HIV]
Ninety percent of Malawian women attend at 
least one antenatal visit, although most do not 
present until the mid-to-late second trimester or 
even in the third trimester (average 26 weeks). 
So for PMTCT, it is important to start early in 
pregnancy to optimally reduce transmission to 
the infant.  Malawi pioneered an approach of 
treating all HIV positive pregnant women re-
gardless of CD4 cell count at the initial visit in 
which they were identified as positive. (Option 
B+)  This has resulted in over a 700% increase 
in the number of HIV infected women starting 
ART.
  
Tell me about the impact on economic and social 
development that the HIV/AIDS epidemic has 
had in Malawi.  UNAIDS discusses the increased 
impact on women as well as the devastation in 
fields that employ women such as teachers and 
healthcare workers (HCW).  
Certainly, several areas have been affected by 
the HIV epidemic including teachers, health-
care workers, military, and police.  With respect 
to HCW and teachers, the numbers required to 
provide services is well below requirements; up 
to 70 or 80% of positions in government facili-
ties are unfilled according to the different health 
care cadres.  And education is the backbone for 
the future.  Despite the AIDS epidemic, Mala-
wi had enormous population growth (2.8% per 
annum), such that the need for these positions 
will be even more important.    This population 
growth is a major barrier to development in 
Malawi.
Is your institution able to target rural populations 
as well?  What are the different barriers to care 
between rural and urban affected populations?
Yes, our programs target some rural communi-
ties, as we extend our catchment area to 50km 
from our facility.  This includes rural commu-
nities. Distance to health facilities becomes a 
larger barrier for rural communities.
What have been some of the roadblocks to health-
care for people infected with HIV/AIDS in Mala-
wi.  Are patients able to obtain the medications 
they need?  Who provides the medications for 
those that cannot afford the drugs?  
The ART has been free since 2004, so that ART 
drug cost is not a barrier.  However, the trans-
port costs to get to clinics are difficult for the ru-
ral poor.   The ART program, (funded through 
the Global fund with a parallel procurement 
system) has safeguards to prevent stock-outs. 
For general health care in Malawi, all govern-
ment hospitals and clinics are free.  However, 
for medications that are not provided through 
the Global Fund, medications are frequently out 
of stock, and patients will depart clinics without 
these medications.  Also, if they are admitted to 
the hospital, there are common stock-outs of es-
sential medications and supplies.   In these sce-
narios, patients would go without.   [The Global 
Fund to Fight AIDS, Tuberculosis, and Malaria]
You mentioned that you are able to provide ART 
through your clinic to patients, but once they are 
hospitalized they may not have access to many of 
the medications they need.  Is that ART as well as 
antibiotics, etc?  Does the act of being hospital-
ized become a marker for increasing mortality? 
Stated in another way, when an elderly person 
falls and breaks a hip, no matter what their health 
capacity was prior to the break, their incidence of 
all-cause mortality rises significantly during the 
year after the break.  Do you see a “this is the be-
ginning of the end” scenario when your patients 
ultimately do need hospitalization?
ART would still be available to the patient, 
as they can either get an emergency supply 
through the hospital clinic, the ART clinic, or 
they can take their own.  I don’t think the same 
holds entirely with our HIV infected patients, as 
usually the problem is largely reversible if they 
can get through the acute period.  But, that gives 
me a research idea to evaluate the outcomes of 
patients who have had admissions and what fol-
lows thereafter.
I remember the day I ruled out a career in In-
fectious Diseases.  I have vivid memories of one 
particular patient who died from an AIDS-re-
lated illness.  Unfortunately, sometimes we were 
just too late to make a difference, especially in 
the early days of ART.  I know you must have had 
experiences during residency just like that, but 
somehow you decided to face it head on.  I am cu-
rious about that.  Was there a particular patient 
that affected your decision to go into Infectious 
Diseases?
While I won’t target a particular patient, I was 
rather struck by how, as an intern in 1995/96, 
there was complete hopelessness to HIV, but by 
the time I was in my third year as a resident and 
ART was now more available, the number of 
dying AIDS patients on my service was lower. 
By going to the HIV clinic, I could see the hope 
and reality of HIV treatment.   I see the exact 
same phenomenon in Africa.  When I arrived 
in 2001, death was the reality for HIV patients. 
Now, my clinic is a lot of healthy people going 
about their usual lives.  Imagine if your patient 
had survived, if you had reversed his course….
going from a bedridden state, to walking with 
a cane, to coming into your office with his new 
born baby.  It is transformative.
 
What is the typical lifespan of someone who has 
received optimal treatment of HIV now?  What 
are the causes of mortality for patients with HIV 
today?
I haven’t taken care of HIV infected patients in 
the US for some time now, but life expectancy 
for most HIV infected patients in care (I clarify 
“in care”) actually approaches that of HIV unin-
fected individuals.  And the spectrum of illness-
es faced by HIV infected patients is similar to 
that of any aging population, including cardio-
vascular disease, liver disease, and renal disease. 
Grassroots & Citizen 
Involvement in HIV.
I know that UNAIDS has several NGO’s on its pro-
gram coordination board.   Personally, I see the 
integration of the field of HIV/AIDS with citizen 
diplomacy as being not only an early vanguard 
of that type of arrangement, but also a model of 
cooperation and mutual respect. Could you touch 
on the role that these types of groups have played 
in your field?  You mentioned that some of these 
groups can be helpful because they provide access 
to medications outside the “usual channels”.  That 
certainly reflects influence at a very local level. 
What about higher up in the policy making and 
funding choices you see in the field?
Certainly community advocacy groups are a 
part of the HIV campaign and make their voic-
es heard, particularly at the World AIDS con-
ference.  But, more of the meetings and confer-
ences that I attend focus on the science of HIV. 
Our research groups have community constit-
uency groups that are part of the scientific pro-
cess, so that we remain actively engaged in the 
needs of community.  On a local level in Ma-
lawi, our site has a community advisory board 
and an active community program in charge of 
education.  For most policy decisions in which 
I’m involved, we really focus on the technical as-
pect of decision-making, and then the decisions 
are presented to the wider range of stakehold-
ers.  This ensures that decisions can remain evi-
dence-based, rather than appealing to particular 
groups.
 
Do you see large international agencies as a help 
or a hindrance in trying to provide medical care 
and social support for Malawians affected with 
HIV?  In what ways?
I think they are helpful because they increase the 
human workforce and often provide supplies in 
a way that does not go through the inefficient 
(and often corrupt) systems of the Malawi gov-
ernment channels.
Tell me what you like about living in Malawi (or 
Africa in general)  (Many Patterson students go 
on to international careers, often in developing 
countries, or in places that no one else has an in-
terest in going!)  
Well, as an expatriate, you have a pretty good 
quality of life in the sense that you can live se-
curely and can afford to hire staff to help with 
the garden, cleaning, cooking, or child care.  The 
community is also geared to have immediate so-
cial circles, usually with other expats also living 
abroad.  It is sometimes unfortunate how easy it 
is to integrate with the other expats, as it limits 
your interactions with Malawians. But, I’ve been 
in Malawi long enough that I have some Malawi 
social circles as well, and you end up feeling like 
you live in a small town.
 
What about living and working in Malawi keeps 
you there? 
I think the work is the big component.  The 
range of activities from teaching, research, clini-
cal care, and policy development makes for con-
tinued excitement and challenges.
 
Dr Hosseinipour, thank you so much for sharing 
your insights with us.  It is truly difficult to fath-
om the progress that has been made in the last 12 
years since you arrived in Malawi.  Congratula-
tions and best wishes to you and the UNC-Malawi 
Project.  
Dr. Dannette Smith Cook is a first year Master’s 
Candidate in Diplomacy at The Patterson School. 
She is certified in internal medicine by The Amer-
ican Board of Internal Medicine and a Fellow in 
the American College of Physicians.   Dr. Cook 
is a practicing hospitalist in Somerset, Kentucky.
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